Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

Completed · Phase 1

Conditions studied: Prostate Cancer

In brief

Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301EXT is an open-label, nonrandomized, phase 1 extension study of PSMA ADC administered IV in subjects with progressive CMPC that has progressed after prior taxane therapy. Subjects who have participated in PSMA ADC 1301 and who, in the opinion of the PI, are likely to benefit from continued treatment with PSMA ADC will be enrolled in PSMA ADC 1301EXT.

Key facts

Study ID

NCT01414296

Run by

Progenics Pharmaceuticals, Inc.

People needed

10

Starts

2009-01-01

Expected to finish

2013-11-01

Last updated by the study team

2013-11-14

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Subjects who have completed the PSMA ADC 1301 study and who, in the opinion of the investigator, have derived benefit from treatment with PSMA ADC.
• A diagnosis of progressive, castration-resistant, metastatic prostate cancer.
• Prior chemotherapy regimens, one of which contains taxane.
• Eastern Cooperative Oncology Group status of 0 or 1

You may not qualify if…

• Clinically significant cardiac disease or severe debilitation pulmonary disease
• Evidence of an active infection requiring ongoing antibiotic therapy
• History of drug and/or alcohol abuse

Where it is running

• Progenics Pharmaceuticals, Inc. — Tarrytown, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.